Wellness
August 13, 2026·6 min read
If you've been hearing about semaglutide and wondering whether it's right for you — or whether what you've seen advertised is even the same thing we offer here in Yuma — this post is for you. There's a lot of noise in this space right now, and I'd rather give you the honest version than a polished marketing answer.
GLP-1 stands for glucagon-like peptide-1. It's a hormone your gut releases after you eat — one of the signals your body uses to tell your brain you're full, slow down gastric emptying, and regulate insulin release. GLP-1 receptor agonists are medications that mimic that signal.
Here's the three-part version: When you eat, GLP-1 is released from cells in your small intestine. It slows the rate at which your stomach empties, reduces appetite signaling in the brain, and improves how your body handles glucose. GLP-1 receptor agonists keep that signal active longer and at a higher level than your body would produce on its own.
Tirzepatide adds a second mechanism — it also activates GIP receptors, another gut hormone involved in insulin response and fat storage. That dual-receptor action is what makes it a distinct class from semaglutide, not simply a stronger version of the same thing.
The result, for many people, is a meaningful reduction in appetite and a shift in how food-driven urges feel — which makes the behavioral work of weight management more manageable. These are tools. They work alongside changes in nutrition, movement, sleep, and stress management. They don't replace any of those things.
For a comprehensive review of GLP-1 receptor agonist pharmacology, the National Library of Medicine's overview of GLP-1 receptor agonist mechanisms is a useful starting point for the peer-reviewed literature.
This is the part of the conversation most marketing skips, and I think it's the most important.
Wegovy®, Ozempic®, Mounjaro®, and Zepbound® are branded, FDA-approved finished pharmaceutical products manufactured by Novo Nordisk and Eli Lilly. They have gone through the full FDA approval process for their specific labeled indications. We do not dispense those branded products at Enhance Aesthetics & Wellness.
What we offer are compounded semaglutide and compounded tirzepatide — 503A compounded preparations dispensed under patient-specific prescriptions following individualized medical evaluation. Compounded preparations are not FDA-approved finished pharmaceutical products. The FDA approvals held by the branded products do not transfer to compounded versions. Efficacy and safety data from clinical trials of the branded products may not apply directly to compounded preparations.
I tell every prospective client this before we talk about anything else. The distinction isn't legal fine print — it's clinically meaningful information you deserve to have before making a decision.
Compounded medication disclosure: The semaglutide and tirzepatide preparations dispensed by Enhance Aesthetics & Wellness are 503A compounded preparations, not FDA-approved finished pharmaceutical products. They are not the same as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®. The FDA approvals held by Novo Nordisk's branded semaglutide products and Eli Lilly's branded tirzepatide products do not transfer to compounded versions. Efficacy and safety data published in clinical trials of those branded products may not apply directly to compounded preparations.
For more on what 503A compounding means and how it's regulated, the FDA's overview of 503A compounding pharmacy requirements provides the regulatory framework.
Every client who comes in for a GLP-1 consultation goes through a medical screening. Not a questionnaire — a real clinical evaluation with Marina Roloff, DNP, FNP-C, that includes labs, health history, and a conversation about what you're trying to accomplish and why.
Some people are not candidates. That's not a sales problem — it's medicine working the way it's supposed to.
Specifically, GLP-1 receptor agonists are not appropriate for people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). They are also not appropriate during pregnancy or while breastfeeding. These are the same contraindications listed in the boxed warning for the branded products, and they apply regardless of whether the medication is compounded or branded.
Beyond the hard contraindications, we look at your full health picture. Clients on certain diabetes medications, those with a history of pancreatitis or gallbladder disease, and clients with complex GI conditions get a more detailed conversation before any decision is made.
Risks and contraindications: GLP-1 receptor agonists carry known risks including nausea, vomiting, constipation, gallbladder disease, and pancreatitis. Less commonly: hypoglycemia (especially in clients on diabetes medications), severe gastrointestinal complications, and rare allergic reactions. The labeled boxed warning for the branded products warns of risk of thyroid C-cell tumors; clients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not take these medications. Pregnant and breastfeeding clients are not candidates.
I'm not going to cite a trial percentage and let you assume it applies to what we offer here. That wouldn't be honest.
The clinical trials of branded semaglutide and tirzepatide products showed meaningful average weight-loss outcomes over 68 to 72 weeks in large controlled populations. Those numbers are real — for those specific branded products, in those specific populations, at those specific doses, with that level of behavioral support built into the trial design. They are not a guarantee of what any individual will experience on a compounded preparation at any practice.
What I can tell you is that the mechanism is well-documented, the physiological rationale for appetite and weight effects is sound, and for people who are medically appropriate candidates and committed to the lifestyle work alongside the medication, meaningful changes in weight and metabolic markers are a reasonable goal. The American Association of Clinical Endocrinology (AACE) obesity guidelines provide a useful framework for how these medications fit into a comprehensive weight-management approach.
Individual results depend on dose, duration, baseline weight, metabolic health, and how consistently you're working on nutrition, movement, and sleep alongside the medication.
Individual results vary: Weight-loss outcomes depend on individualized factors including dose, duration, baseline weight, metabolic health, and lifestyle. Average weight-loss percentages reported in trials of branded products are not a guarantee of individual outcomes on compounded preparations or any specific protocol at Enhance Aesthetics & Wellness.
Our health and wellness programs are built around this kind of medically supervised, individualized approach — not a standard protocol applied to everyone who walks in.
For weight management specifically, here's what the process looks like: We start with a consultation that includes labs and a full health history review. If you're a candidate, we build a program that includes the compounded GLP-1 preparation, dose titration over time, regular check-ins to monitor how you're responding, and ongoing conversation about the nutrition and lifestyle factors that determine whether the medication is working as well as it can for you. For more on how we structure these programs, you can review our weight management program information.
I manage the prescriptions, the titration, and the follow-up. This is medically supervised care — meaning a clinician with prescribing authority is involved in every step, not just the initial intake.
The first conversation is exactly that — a conversation. We figure out together whether this is the right approach for you, whether you're a good candidate, and what a realistic program looks like. There's no pressure to start anything in that visit.
If you'd like to talk through whether a GLP-1 program might be appropriate for your situation, you can reach us at 928.370.4480 or schedule a consultation through our health and wellness page.
Standard site-wide disclaimer: Information on this page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Individual results vary; outcomes shown or described are not guaranteed. Compounded medications referenced (including GLP-1 receptor agonists) are prepared by licensed compounding pharmacies under 503A patient-specific prescriptions and are not FDA-approved finished pharmaceutical products. Consult an Enhance clinician for guidance specific to your situation. Images may contain models. © 2026 Enhance Aesthetics & Wellness.
Medically reviewed by Marina Roloff, DNP, FNP-C — 2026-08-13
Schedule a Consultation
Marina Roloff, DNP, FNP-C — Enhance Aesthetics & Wellness, Yuma, AZ
CONTACT US